The aim of this report is to assess the added benefit of fidaxomicin according to its approval for the following therapeutic indication: treatment of Clostridium difficile infections (CDI) also known as Clostridium difficile-associated diarrhoea (CDAD).
http://ift.tt/2ruBHkm
Πέμπτη 15 Ιουνίου 2017
Fidaxomicin -- Benefit Assessment According to §35a Social Code Book V [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου